(Q41902026)

English

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

scientific article published on 5 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1 reference

based on heuristic

inferred from title

2

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

author name string

Stuart L Goldberg

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Michael D Craig

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Emmanuel Gyan

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

John Lister

5

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Jeannine Kassis

6

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Arnaud Pigneux

7

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Gary J Schiller

8

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

JungAh Jung

9

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

E Jane Leonard

10

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Howard Fingert

11

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Peter Westervelt

12

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

publication date

5 July 2014

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Leukemia research reports

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

58-61

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

Aurora kinase inhibitors--rising stars in cancer therapeutics?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

Clinical experience with aurora kinase inhibitors: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

5 June 2018

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

18 August 2018

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110881

18 August 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25068104

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.LRR.2014.06.003

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

release_iwi2oojjfnhsxlsccyhqck6wje

1 reference

https://api.fatcat.wiki/v0/release/iwi2oojjfnhsxlsccyhqck6wje

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41902026&oldid=1929572033"